Affimed NV股票讨论区

$Affimed NV(AFMD.US)$
NEWS
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (Nasdaq: AFMD) announces the acceptance of the AFM24 clinical abstract at the 2024 ASCO Annual Meeting. The phase 2 study on AFM24 in combination with atezolizumab in patients with EGFR wild-type non-small cell lung cancer has been accepted for poster presentation. The abstract will be available on ASCO's website on May 23, 2024.

$SPDR标普生物科技ETF(XBI.US)$
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x % $Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

$Affimed NV(AFMD.US)$
Dump the Junk

$Affimed NV(AFMD.US)$ Affimed Announces Sale of Wholly Owned Subsidiary AbCheck

$Affimed NV(AFMD.US)$ will it reach $1 in 2024?

$Affimed NV(AFMD.US)$ Should be above $0.50 and above in 2024.

$Affimed NV(AFMD.US)$ Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)